Merck & Company, Inc. vs Pfizer, Inc. — Valuation Comparison 2026
Access all valuation models for MRK vs PFE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MRK scores higher with a 9.8/10 quality rating vs PFE's 6.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Merck & Company, Inc. (MRK) and Pfizer, Inc. (PFE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
MRK currently trades at $119.89 with a QOC of 9.8/10, while PFE trades at $26.14 with a QOC of 6.7/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).